Telix Pharmaceuticals Limited (TLPPF)

15.90

0.00

(0.00%)

As of April 22 at 4:00:00 PM EDT. Market Open.

Telix Reports US$186M Q1 Revenue, Up 62% YOY

MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 March 2025 (Q1 2025). All figures are in $US unless stated otherwise. Strong Q1 2025 revenue growth Q1 2025 unaudited revenue of approximately $186 million represents an increase of 62% over the prior year corresponding quarter (Q1 2024: $115M) and a quart

GlobeNewswire yesterday

TLPPF
0.00%
TLX
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients

Telix Pharmaceuticals Limited (NASDAQ:TLX) on Tuesday released preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study. IPAX-Linz is a single-arm Phase 2 investigator-initiated trial evaluating the safety, tolerability, and preliminary efficacy of TLX101 therapy in combination with external beam radiation therapy (EBRT). TLX101 (131I-iodofalan or 131I-IPA) is a syst

Benzinga 7 days ago

TLX.AX
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2].

PR Newswire 7 days ago

TLPPF
0.00%
TLX
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

Telix Pharmaceuticals Limited (TLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 9 days ago

TLX.AX
Telix Announces Cardinal Health for Gozellix Commercial Distribution

MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging1 agent for prostate cancer in the United States (U.S.

GlobeNewswire 15 days ago

CAH

TLPPF
0.00%
TLX
Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today. Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada’s particle accelerator research centre, since 2012. Based in Van

GlobeNewswire 16 days ago

TLPPF
0.00%
TLX
Anne Whitaker Appointed as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years’ global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and

GlobeNewswire 19 days ago

TLPPF
0.00%
TLX

ICLR
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

MELBOURNE, Australia, April 02, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZOLAR1 trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne, Australia. ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET)

GlobeNewswire 21 days ago

TLPPF
0.00%
TLX
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®

BURNABY, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Telix ARTMS, Inc. (ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug master file (DMF)1 for gallium-68 production using its QUANTM Irradiation System® (QIS®) cyclotron technology has been referenced for the first time with a United States (U.S.) Food and Drug Administration (FDA) approved product, with Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection). Thi

GlobeNewswire 22 days ago

TLPPF
0.00%
TLX
FDA Approves New Prostate Cancer Imaging Agent Gozellix®

MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging1 agent for prostate cancer. Gozellix®, after radiolabeling with 68Ga, is indicated for PET

GlobeNewswire last month

TLPPF
0.00%
TLX
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approved Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) the Company's lead prostate cancer imaging agent. Illuccix® is the first and only PSMA-PET[1] prostate cancer imaging agent to receive full regulatory approval in Brazil.

PR Newswire last month

TLPPF
0.00%
TLX
Telix Adds Lead-212 Isotope Production Capability

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production.

PR Newswire last month

TLPPF
0.00%
TLX
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company's late-stage and next-generation radiotherapeutic candidates in urologic oncology.

PR Newswire last month

TLPPF
0.00%
TLX
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET[1] imaging agent TLX250-CDx (Zircaix®[2], 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA[3] date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.

PR Newswire last month

TLPPF
0.00%
TLX
Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami

MELBOURNE, Australia and INDIANAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) announces that the Biogenix Molecular Research Center in Miami, FL, is recruiting and dosing patients in the ProstACT Global Phase 3 trial1 of TLX591 for patients with advanced prostate cancer, as part of a wider United States (U.S.) roll-out. ProstACT Global is trialling a promising new treatment option for prostate cancer, which is the most commonly

GlobeNewswire last month

TLPPF
0.00%
TLX
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?

Telix Pharmaceuticals Limited (TLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

TLX
Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...

Telix Pharmaceuticals Ltd (TLPPF) reports a remarkable 56% revenue increase and outlines strategic plans to navigate regulatory challenges and expand market reach.

GuruFocus.com last month

TLX.AX
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces its financial results for the year ended 31 December 2024. All figures are in AU$ unless stated otherwise.

PR Newswire 2 months ago

TLPPF
0.00%
TLX
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

MELBOURNE, Australia and INDIANAPOLIS, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces presentations featuring the Company’s late-stage and next generation therapeutic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) to be held in San Francisco, CA (US) from 13 – 15 February 2025. Dr. David N. Cade, Telix Group Chief Medical Officer, said, “Telix will feature i

GlobeNewswire 2 months ago

TLPPF
0.00%
TLX
Illuccix® Approved in the United Kingdom

MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection). Illuccix is indicated in the UK for the detection and localization of prostate-specific memb

GlobeNewswire 2 months ago

TLPPF
0.00%
TLX

Performance Overview

Return	TLPPF	S&P/ASX 200 [XJO] (^AXJO)
YTD	+6.18%	-2.92%
1-Year	+73.96%	+3.08%
3-Year	+354.29%	+5.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Telix Pharmaceuticals Limited (TLPPF)

Telix Reports US$186M Q1 Revenue, Up 62% YOY

Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

Telix Announces Cardinal Health for Gozellix Commercial Distribution

Telix Appoints Paul Schaffer as Chief Technology Officer

Anne Whitaker Appointed as Non-Executive Director

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Telix Adds Lead-212 Isotope Production Capability

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami

Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?

Telix Pharmaceuticals Ltd (TLPPF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ...

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Illuccix® Approved in the United Kingdom

Performance Overview